顺铂联合化疗可诱导晚期非小细胞肺癌患者产生氧化应激。

Cisplatin combination chemotherapy induces oxidative stress in advance non small cell lung cancer patients.

作者信息

Srivastava Anand Narain, Gupta Abhilasha, Srivastava Shruti, Natu S M, Mittal Balraj, Negi M P S, Prasad Rajendra

机构信息

Department of Pathology, Era's Lucknow Medical College and Hospital, Sarfarazganj, Moosa bagh, Picnic spot, India.

出版信息

Asian Pac J Cancer Prev. 2010;11(2):465-71.

PMID:20843135

Abstract

BACKGROUND

This study determine oxidative stress and survival prospectively in advanced stage non small cell lung cancer (NSCLC) patients following cisplatin based combination chemotherapy.

MATERIALS AND METHODS

The oxidative stress levels (LPO, NO, GSH and SOD) of 144 control subjects and 203 advanced stage (IIIA/IIIB/IV) newly diagnosed NSCLC patients were assessed at pre-treatment (day '0'), and after the 3rd and 6th cycles of chemotherapy. Groups were compared by repeated measures ANOVA while comparison of survival curves was conduced by Kaplan-Meier methods.

RESULTS

The pre-treatment mean levels of LPO and NO in patients were significantly (P<0.01) higher while GSH and SOD were significantly (P<0.01) lower as compared to control. The oxidative stress was elevated more significantly (P<0.01) after the chemotherapy and was more evident in higher stage than lower stage patients. The two year overall survival (%) of stage IV patients was significantly lower (P<0.05) as compared to stage III A and III B. The proportional mortality was also maximal in stage IV patients (37.0%) followed by stage III B (31.7%) and III A (20.0%).

CONCLUSION

Cisplatin based combination chemotherapy induces oxidative stress in NSCLC patients.

摘要

背景

本研究前瞻性地确定了晚期非小细胞肺癌（NSCLC）患者接受基于顺铂的联合化疗后的氧化应激和生存情况。

材料与方法

对144名对照受试者和203名新诊断的晚期（IIIA/IIIB/IV期）NSCLC患者在治疗前（第0天）以及化疗第3周期和第6周期后评估氧化应激水平（LPO、NO、GSH和SOD）。采用重复测量方差分析对各组进行比较，同时采用Kaplan-Meier方法比较生存曲线。

结果

与对照组相比，患者治疗前LPO和NO的平均水平显著更高（P<0.01），而GSH和SOD显著更低（P<0.01）。化疗后氧化应激升高更为显著（P<0.01），且在晚期患者中比早期患者更明显。IV期患者的两年总生存率（%）显著低于IIIA期和IIIB期（P<0.05）。IV期患者的比例死亡率也最高（37.0%），其次是IIIB期（31.7%）和IIIA期（20.0%）。